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COMPARISION OF FIBROMETER TEST WITH FIBROSCAN AND 
ITS CORRELATION WITH LIVER BIOPSY IN DETECTING LIVER 
FIBROSIS IN PATIENTS WITH HEPATITIS B INFECTION. 
INTRODUCTION: 
 Hepatitis B is a major health problem affecting more than 350 million 
people globally. Hepatitis B carriers are defined as persons positive for HBsAg 
for more than 6 months. The chance of developing sequelae is about 15% to 
40% over lifetime, hence evaluation and early treatment is required. The 
prognosis and management of HBV related liver disease depends on the degree 
of liver fibrosis 
AIM: 
The aim of the study was to detect liver fibrosis in patients with chronic 
hepatitis B infection using non invasive markers – Fibroscan and Fibrometer 
test and to compare its efficacy with the gold standard liver biopsy. 
MATERIALS AND METHODS: 
 This prospective study was conducted in our department, Department of 
Digestive Health and Disease, Kilpauk Medical College, Chennai. 30 patients 
were included in our study over a period of six months. Patients with Chronic 
hepatitis B infection alone were included in the study. Patients with associated 
HCV/HIV infection, compensated or decompensated cirrhotics were excluded 
from the study. Detailed history, physical examination was performed and 
baseline hematologcal investigations, Fibroscan, Fibrometer and Liver biopsy 
were also done. 
 
 
RESULTS: 
 In our study, out of 30 patients 21 (70%) were males and 9 (30%) were 
females. 63% of the study population were HBeAg negative and 63.33% of the 
patients had high viral load of more than 1,00,000 IU/ml. Patients underwent 
Fibroscan study which showed 14 patients (46.67%) had liver stiffness 
measurement (LSM) of less than 6.5 kpa suggesting nil fibrosis, 33% had mild 
fibrosis with a LSM value of 6.5 to 8 and 20% had values above 8 suggesting 
moderate fibrosis. Similarly Fibrometer test showed 43.33% patients with 
significant fibrosis. Statistical analysis was done by Pearson co-efficient 
equation and it showed that Fibroscan value (LSM) of more than 8 kpa had 
100% specificity in detecting significant fibrosis correlating with liver biopsy 
with a p value of 0.005 and ROC of 0.89 (95% confidence interval of 0.76 to 
0.90). Fibrometer test also detected significant fibrosis (F2) in 43% of patients 
and on correlation with liver biopsy had a P value o 0.004 with ROC values of 
0.905 and 95% confidence interval of 0.80 – 0.99.  
CONCLUSION: 
 Fibroscan and Fibrometer is good non-invasive test only in detecting 
significant fibrosis, with higher values correlating with liver biopsy. Liver 
biopsy still is the gold standard and is useful in detecting early fibrosis. Both 
Fibroscan and Fibrometer has similar efficacy and can be used to exclude 
fibrosis and to detect significant fibrosis. 
